Abstract
AbstractModulation of tryptophan metabolism and in particular the kynurenine pathway is of considerable interest in the discovery of potential new treatments for neurodegenerative diseases. A number of small molecule inhibitors of the kynurenine metabolic pathway enzymes have been identified over recent years; a summary of these and their utility has been reviewed in this chapter. In particular, inhibitors of kynurenine monooxygenase represent an opportunity to develop a therapy for Huntington’s disease; progress in the optimization of small molecule inhibitors of this enzyme is also described.KeywordsEnzyme inhibitorsHuntington’s diseaseKynurenine monooxygenase (KMO)Kynuremine pathwayNeurodegenerative diseaseTryptophan Metabolism
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
